Source comparison
Best Research Peptides for Meniscus Injury: Mechanism Comparison
BPC-157 VEGF upregulation, eNOS activation, angiogenesis Inflammation → Early Proliferation (0–21 days) Red-white, white-white zones 10–20 mcg/kg daily IP in rodents; human dosing undefined 40+ preclinical studies; no Phase III human trials Lead candidate for
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation, eNOS activation, angiogenesis
- Inflammation → Early Proliferation (0–21 days)
- Red-white, white-white zones
- 10–20 mcg/kg daily IP in rodents; human dosing undefined
- 40+ preclinical studies; no Phase III human trials
- Lead candidate for avascular meniscal tears due to robust angiogenic signaling. Mechanism addresses the core vascular limitation
- TB-500 (Tβ4 fragment)
- Actin sequestration, cellular migration, laminin-5 upregulation
- Proliferation → Early Remodeling (14–56 days)
- All zones (migration-dependent)
- 2 mg 2×/week × 4 weeks loading, then 2 mg weekly maintenance in animal models
- 25+ preclinical studies; equine trials show efficacy; no human RCTs
- Best for established injuries where inflammation resolved but collagen deposition stalled. Migration mechanism works independent of vascularity
- GHK-Cu
- MMP downregulation, TIMP upregulation, lysyl oxidase activation
- Remodeling (8 weeks onward)
- All zones (matrix-dependent)
- 1–3 mg/kg subcutaneous 3×/week in rodent collagen studies
- 60+ studies on wound healing; limited meniscal-specific data
- Required for long-term tissue integrity. Prevents premature collagen degradation during stress reintroduction
- IGF-1 LR3
- IGF-1 receptor agonism, protein synthesis, satellite cell proliferation
- Proliferation (muscle/tendon; limited meniscal data)
- Red-red zone primarily
- 40–80 mcg daily subcutaneous in bodybuilding protocols (off-label, not research dosing)
- Extensive muscle hypertrophy research; minimal cartilage evidence
- Weak candidate for meniscal injuries. Mechanism better suited to muscle/tendon repair than fibrocartilage
- Ipamorelin + CJC-1295
- Growth hormone secretagogue; systemic IGF-1 elevation
- Systemic anabolic state (indirect cartilage benefit)
- Non-specific
- 200–300 mcg combined dose 1–2×/day in anti-aging protocols
- No meniscal-specific research; general growth hormone literature only
- Indirect benefits possible through systemic IGF-1 elevation but lacks tissue-specific targeting. Not first-line for localized meniscal injury